Beijing Beilu Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021
October 27, 2021 at 04:37 am EDT
Share
Beijing Beilu Pharmaceutical Co., Ltd. reported earnings results for the nine months ended September 30, 2021. For the nine months, the company reported sales was CNY 680.84 million compared to CNY 623.55 million a year ago. Revenue was CNY 680.84 million compared to CNY 623.55 million a year ago. Net income was CNY 129.74 million compared to CNY 160.5 million a year ago. Basic earnings per share from continuing operations was CNY 0.2653 compared to CNY 0.3282 a year ago.
Beijing Beilu Pharmaceutical Co., Ltd is a China-based company principally engaged in the research, development, production and distribution of contract medium products, anti-diabetic products and anti-anxiety products. The Companyâs main products include gadopentetate dimeglumine injection, iohexol injection, Iodoparol injection, Iodixanol injection, ferric ammonium citrate effervescent granules, repaglinide tablets, glimepiride tablets, Jiuwei Zhenxin granules, among others. The Company mainly distributes its products in domestic market.